Eyenovia, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30234E1047
  • NASDAQ: EYEN
USD
3.92
-0.07 (-1.75%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Eyenovia, Inc.
Alpha Teknova, Inc.
DURECT Corp.
G1 Therapeutics, Inc.
ADC Therapeutics SA
Corvus Pharmaceuticals, Inc.
Immix Biopharma, Inc.
Evelo Biosciences, Inc.
Kinnate Biopharma, Inc.
Tiziana Life Sciences Ltd.
Zynerba Pharmaceuticals, Inc.

Why is Eyenovia, Inc. ?

1
With a growth in Net Sales of INF%, the company declared Outstanding results in Jun 26
  • The company has declared positive results for the last 7 consecutive quarters
  • NET SALES(HY) At USD 0.6 MM has Grown at 3,989.43%
  • OPERATING CASH FLOW(Y) Highest at USD -13.98 MM
  • ROCE(HY) Highest at 9.55%
2
With ROE of -23.72%, it has a risky valuation with a 0.40 Price to Book Value
  • Over the past year, while the stock has generated a return of -61.21%, its profits have risen by 51%
3
Rising Promoter Confidence
  • Promoters have increased their stake in the company by 1.96% over the previous quarter and currently hold 1.96% of the company
  • Promoters increasing their stake is a sign of high confidence in the future of the business
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Eyenovia, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Eyenovia, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Eyenovia, Inc.
-61.21%
-0.82
113.79%
S&P 500
15.76%
1.20
13.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
6.19%
EBIT Growth (5y)
-1.40%
EBIT to Interest (avg)
-14.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.68
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
28.22%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.40
EV to EBIT
-1.25
EV to EBITDA
-1.27
EV to Capital Employed
0.39
EV to Sales
27.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-31.54%
ROE (Latest)
-23.72%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

36What is working for the Company
NET SALES(HY)

At USD 0.6 MM has Grown at 3,989.43%

OPERATING CASH FLOW(Y)

Highest at USD -13.98 MM

ROCE(HY)

Highest at 9.55%

DEBTORS TURNOVER RATIO(HY)

Highest at 5.69 times

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

PRE-TAX PROFIT(Q)

Highest at USD 15.21 MM

NET PROFIT(Q)

Highest at USD 15.21 MM

EPS(Q)

Highest at USD 0.92

0What is not working for the Company
NO KEY NEGATIVE TRIGGERS

Here's what is working for Eyenovia, Inc.

Net Sales
At USD 0.6 MM has Grown at 3,989.43%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit
At USD 15.21 MM has Grown at 274.96%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 15.21 MM has Grown at 274.96%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Cash Flow
Highest at USD -13.98 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debtors Turnover Ratio
Highest at 5.69 times and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Pre-Tax Profit
Highest at USD 15.21 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD 15.21 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD 0.92
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Footer loading